On August 3, 2026 Adlai Nortye Ltd. (NASDAQ: ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, reported that it has submitted a Clinical Trial Notification (CTN) to Australia’s Therapeutic Goods Administration (TGA) and received approval from the Human Research Ethics Committee (HREC) to commence its phase I clinical trial evaluating AN4035, a CEACAM5-targeting, pan-RAS(ON) inhibitor-based antibody drug conjugate (ADC) for the treatment of CEACAM5-enriched RAS-addicted solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"AN4035 is a first-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor payload, and is our first drug candidate to demonstrate proof-of-concept of our RASiCA (RAS Inhibitor Conjugated Antibody) platform." said Dr. Archie Tse, President, Head of Research & Development. "To our knowledge, AN4035 is the first pan-RAS(ON) ADC to enter the clinic globally. We believe that utilizing targeted delivery via an ADC could localize pan-RAS(ON) inhibitor activity to the tumor while minimizing systemic RAS pathway inhibition, which could potentially both widen the therapeutic window and enable rational combinations. We are excited to see this asset advance into clinical development and the potential benefit it may bring to our patients globally."
This global phase I trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AN4035 as monotherapy and in combination with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors. CEACAM5 is an antigen that is overexpressed in colorectal, pancreatic, and lung cancers, which frequently harbor RAS mutations. Adlai Nortye is also filing investigational new drug (IND) applications for AN4035 with the U.S. Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA). Patient dosing with AN4035 is expected to begin in the second half of 2026.
About AN4035
AN4035 is a first-in-class ADC targeting CEACAM5 and armed with a highly potent pan-RAS(ON) inhibitor payload. In preclinical studies, AN4035 demonstrated nanomolar to picomolar cytotoxicity in CEACAM5-positive / RAS-addicted cancer cell lines, along with a robust bystander killing effect. It also exhibited potent anti-tumor activity with deep regression in CDX/PDX models, favorable developability with desirable pharmacokinetic properties, and enhanced target-mediated tumor retention with improved tumor selectivity over normal tissue — resulting in an overall favorable therapeutic index. Adlai Nortye is evaluating AN4035 in a global phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors.
(Press release, Adlai Nortye Biopharma, AUG 3, 2026, View Source [SID1234669633])